GenomOncology collaborates with RPCI to develop informatics solution for Next Generation Sequencing

NewsGuard 100/100 Score

GenomOncology today announced a collaboration with Roswell Park Cancer Institute (RPCI) to develop an informatics solution that enables the association of Next Generation Sequencing results with knowledge resources to define actionable mutations. 

"The challenges of translating the vast amounts of data from next-generation sequencing into a resource that can be easily and effectively incorporated into clinical and research programs are significant," said Dr. Carl Morrison, Executive Director of the Center for Personalized Medicine at Roswell Park. "We need next-generation tools that will help us to deliver the best and most appropriate therapies to our patients through a streamlined process."

GenomOncology and RPCI are working together to develop a software platform that integrates laboratory information management systems, electronic health records, information technology and bioinformatics and that provides a workflow enabling genomic analysts and pathologists to create actionable reports.

GenomOncology will be demonstrating this software platform at two upcoming conferences, Advances in Genome Biology & Technology (AGBT) in February and United States & Canadian Academy of Pathology (USCAP) in March.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases